Greg Gerstner, MD
Hematology & Oncology · Peoria, ILNPI 1629288659
Payments from drug & device makers
Across 555 payments — averaging $3024.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$535K
- Bristol Myers Squibb$447K
- Merck$360K
- F. Hoffmann-la Roche AG$155K
- E.r. Squibb & Sons, L.L.C.$60K
- Astrazeneca UK Limited$43K
- plus $78K from 36 others
What the payments were for
- Food & beverage$2,04588%
- Education$23110%
- Gifts$482%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 264 | $535,462 |
| Bristol Myers Squibb | 22 | $446,635 |
| Merck | 67 | $359,887 |
| F. Hoffmann-la Roche AG | 53 | $154,975 |
| E.r. Squibb & Sons, L.L.C. | 19 | $60,172 |
| Astrazeneca UK Limited | 2 | $43,455 |
| Novocure Inc. | 18 | $41,400 |
| Incyte Corporation | 8 | $33,979 |
| AstraZeneca(2 entities) | 9 | $1,134 |
| Seagen Inc. | 12 | $210 |
| Novartis | 11 | $185 |
| Eisai Inc. | 6 | $103 |
| Sanofi | 5 | $97 |
| Genentech USA, Inc. | 5 | $77 |
| Pfizer | 4 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $75 |
| Astellas Pharma US Inc | 4 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $63 |
| Johnson & Johnson | 4 | $60 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $58 |
| Amgen | 2 | $56 |
| Lilly USA, LLC | 3 | $56 |
| AbbVie | 2 | $53 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Tosoh Bioscience, Inc. | 1 | $48 |
| Taiho Oncology, Inc. | 3 | $47 |
| Secura Bio, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Clovis Oncology, Inc. | 1 | $32 |
| EUSA Pharma (US) LLC | 2 | $32 |
| Bayer | 2 | $31 |
| Deciphera Pharmaceuticals Inc. | 1 | $30 |
| Gilead | 2 | $26 |
| GSK | 1 | $21 |
| Advanced Accelerator Applications | 1 | $20 |
| CTI Biopharma Corp. | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| G1 Therapeutics, Inc. | 1 | $12 |
| Verastem, Inc. | 1 | $11 |
How this compares
$1,678,836 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 110 | $1,460,709 |
| JakafiRuxolitinib Phosphate | 69 | $1,129,566 |
| ImbruvicaIbrutinib | 63 | $796,598 |
| RevlimidLenalidomide | 51 | $779,817 |
| BrukinsaZanubrutinib | 59 | $754,275 |
| TagrissoOsimertinib Mesylate | 33 | $517,810 |
| NubeqaDarolutamide | 22 | $304,603 |
| OnuregAzacitidine | 13 | $295,598 |
| XtandiEnzalutamide | 18 | $288,492 |
| VenclextaVenetoclax | 40 | $287,640 |
| PomalystPomalidomide | 11 | $249,227 |
| CalquenceAcalabrutinib Maleate | 12 | $165,378 |
| SprycelDasatinib | 13 | $151,340 |
| Abiraterone Acetate | 57 | $150,563 |
| EliquisApixaban | 121 | $91,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $33,979 | $1,129,56669 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $58 | $796,59863 claims |
| Bristol Myers SquibbRevlimid | $446,635 | $779,81751 claims |
| E.r. Squibb & Sons, L.L.C.Onureg, Pomalyst, Sprycel | $60,172 | $696,16537 claims |
| AstraZenecaTagrisso, Calquence | $1,134 | $683,18845 claims |
| BayerNubeqa | $31 | $304,60322 claims |
| Astellas Pharma US IncXtandi | $64 | $288,49218 claims |
| AbbVieVenclexta | $53 | $287,64040 claims |
| PfizerEliquis | $76 | $91,830121 claims |
| NovartisTasigna | $185 | $64,08912 claims |
| Johnson & JohnsonXarelto | $60 | $11,48312 claims |
| Lilly USA, LLCOlanzapine | $56 | $62879 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Peoria
- Gary MacvicarPeoria$3.1M
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.